<DOC>
	<DOCNO>NCT02999204</DOCNO>
	<brief_summary>To evaluate patient chronic kidney disease impact two dosage per o vitamin D3 supplementation ( cholecalciferol ) large arterial stiffness ( evaluate non invasively pulse wave velocity high-resolution echotracking system ) . We also study arterial calcification ( lateral abdominal radiography echocardiogram ) , arterial remodeling ( high-resolution echotracking system ) , endothelial function ( evaluate non-invasive finger biosensor device ) , bone remodeling ( evaluate serum biomarkers bone mineral density ) .</brief_summary>
	<brief_title>Effect Vitamin D3 Supplementation Arterial Bone Remodeling Chronic Kidney Disease Patients</brief_title>
	<detailed_description>Structural change large artery abnormalities mineral bone metabolism frequent manifestation patient chronic kidney disease ( CKD ) . Together , contribute large part heighten morbidity mortality observe population . Epidemiological data end stage renal disease general population suggest existence bone-vascular axis . Metabolic bone disease ( MBD ) CKD encompass alter bone remodel propensity vascular calcification . These pathological process driven multiple disorder mineral metabolism CKD , among , abnormality vitamin D metabolism . Vitamin D deficiency [ 25 ( OH ) D ] widely observe CKD patient associate increased rate cardiovascular event general population CKD patient . The mechanism involve clearly establish . Vitamin D influence blood pressure effect renin-angiotensin system ( via vitamin D response element renin gene ) , vascular smooth muscle cell cardiomyocyte proliferation hypertrophy , vascular inflammation calcification . Vitamin D deficiency associate large arterial stiffness end-stage renal disease patient . Aortic carotid stiffness independent predictor cardiovascular overall mortality end-stage renal disease patient . Large arterial remodel stiffening could miss pathogenic link vitamin D deficiency increase cardiovascular event rate . In term mineral metabolism , many CKD patient develop secondary hyperparathyroidism . This result combination hyperphosphatemia , hypocalcemia low level active Vitamin D [ 1,25 ( OH ) D2 ] . Since several observational study show parathyroid hormone ( PTH ) level inversely correlate blood 25 ( OH ) D level , possible 25 ( OH ) D deficiency may also contribute hyperparathyroid state . Secondary hyperparathyroidism contribute cardiovascular risk bone disease . Elevated PTH associate large arterial stiffness remodel . Elevated PTH also associate high bone turnover participate development bone disease CKD-MBD . Bone disease CKD-MBD comprises abnormalities bone turnover , mineralization , linear growth strength . Bone biopsy remain gold standard evaluation bone disease CKD invasive nature limit practice . Serum biomarkers bone remodel allow direct estimation bone remodel lack evaluation precision . Among , guideline issue Kidney Disease Improving Global Outcomes ( KDIGO ) recommend PTH ( 1-84 ) bone specific alkaline phosphatase ( BSALP ) . Other biomarkers exist include osteocalcin , osteoprotegerin , tartrate-resistant acid phosphate-5b ( TRAP-5b ) , pyridinoline deoxypyridinoline , procollagen type 1 amino-terminal extension peptide , C terminal cross-link ( CTX ) , FGF-23 fetuin-A . The major limitation use biomarkers kidney-dependent elimination affect measure level depend degree kidney dysfunction . We choose study , addition PTH ( 1-84 ) BSALP , CTX , osteoprotegerin , osteocalcin , fetuin-A fibroblast growth factor-23 ( FGF-23 ) relationship biomarkers arterial disease never demonstrate . This study seek compare impact standard versus aggressive Vitamin D3 supplementation ( Vitamin D deficient CKD patient ) important vascular bone health endpoint .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patients CKD stage 34 [ estimate glomerular filtration rate ( GFR ) modification diet renal disease ( MDRD ) formula 15 60 ml/min/1.73m2 ] . Serum vitamin D level &lt; 50 nmol/L . Patient estimate GFR MDRD formula 15 60 ml/min/1.73m2 ) . Serum vitamin D level &gt; 50 nmol/L . Liver disease manifest elevated alanine aminotransferase ( ALT ) 3 time upper limit normal reference range , elevate gammaglutamyl transferase ( GGT ) total bilirubin level . History malabsorption chronic diarrhea . Patients biphosphonates , estrogen replacement therapy , PTH analog , glucocorticosteroids , calcimimetics , active vitamin D [ 1,25 ( OH ) ] . Patients antiepileptic medication medication affect vitamin D metabolism ( e.g . phenobarbital , phenytoin , rifampicin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>